Markus Eckstein (@Markuseckstein3) header
Markus Eckstein (@Markuseckstein3) profile picture

#Pathologist #Physician Scientist @UniFAU University Hospital Erlangen, Germany #pathology #biomarker_research - My opinions are my own

Erlangen, Germany
Joined July 2017
Photo by Markus Eckstein (@Markuseckstein3)Photo by Markus Eckstein (@Markuseckstein3)Photo by Markus Eckstein (@Markuseckstein3)Photo by Markus Eckstein (@Markuseckstein3)Photo by Markus Eckstein (@Markuseckstein3)Photo by Markus Eckstein (@Markuseckstein3)Photo by Markus Eckstein (@Markuseckstein3)Photo by Markus Eckstein (@Markuseckstein3)Photo by Markus Eckstein (@Markuseckstein3)Photo by Markus Eckstein (@Markuseckstein3)
🌶️🌡️Summary of my uropathology for urologists and oncologists series! 👉check it out! and retweet if you like! @urotoday @OncoAlert @Uroweb @EAUYAUrology @EAU_YAUroTech @EauPatient @niklas_kluemper @onkowissen nitter.gq/Markuseckstein3/status…
Today I will start a new small series: Uropathology for urologists and uro-oncologists. @urotoday @OncoAlert @imedverse Let us start with my favorite topic: Urothelial Cancer! You will often hear urothelial cancer is a heterogeneous disease, but why ?
3
32
2
52
51,025
Markus Eckstein retweeted
🚨 Transformative moment in precision oncology! Targeting the once “undruggable” RAS is becoming clinical reality. 🇪🇺 Daraxonrasib just received EU approval for previously treated metastatic pancreatic cancer! Phase III RASolute 302: median OS 13.2 vs 6.7 months (HR 0.40). Could this be the EV+pembro moment for PDAC? 🔥 Different disease, different mechanism—but a similarly profound shift in treatment. Super exciting times in precision oncology! globenewswire.com/news-relea… @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
11
18
1,227
Markus Eckstein retweeted
🦠 NECTIN4 is not only an ADC target—it is also a viral entry receptor! Fascinating new study in @Nature showing that NECTIN4 mediates rubella virus entry into airway and placental cells. And NECTIN4 is already known as an entry receptor for measles virus! 🎯 An intriguing biological connection: Viruses exploit cell-surface receptors to gain entry, while ADCs such as enfortumab vedotin rely on receptor binding and intracellular payload delivery. Could NECTIN4’s role in viral entry offer clues to why it is such an effective ADC target? Target expression is only part of the story. Receptor trafficking and internalization matter too! 🔬 nature.com/articles/s41586-0… @PTarantinoMD @raffcolo @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
15
34
2,231
Markus Eckstein retweeted
🇮🇳 Team India is brewing up some competition at the Uromigos World Cup! ☕⚽🏆 It's Chai Pe Charcha time! From Mumbai to Cleveland, Team India is exploring whether low-dose immunotherapy could make cancer treatment more affordable and what it might mean for bladder cancer. Cheers to the competition! ☕ 🎥 : @shilpaonc & @adidhanawat | #UromigosLive
11
34
5
102
10,996
Markus Eckstein retweeted
EV binds Nectin-4 at the cell surface, so where it’s expressed matters. In @CCR_AACR, we discuss Klümper et al: a membranous Nectin-4 + NECTIN4 amp score sorts EV ORRs into 77% / 43% / 26%. Next test: EV+pembro. @dsolit @niklas_kluemper @markuseckstein3 🔗doi.org/10.1158/1078-0432.CC…
2
18
1
38
2,125
Thanks @Dr_Aggen for picking that up! The story is evolving to be the best for our patients! Looking forward to pushing that further and contributing a little to future precision oncology for miBC and mUC patients.
EV binds Nectin-4 at the cell surface, so where it’s expressed matters. In @CCR_AACR, we discuss Klümper et al: a membranous Nectin-4 + NECTIN4 amp score sorts EV ORRs into 77% / 43% / 26%. Next test: EV+pembro. @dsolit @niklas_kluemper @markuseckstein3 🔗doi.org/10.1158/1078-0432.CC…
3
8
571
Markus Eckstein retweeted
Thanks for picking our study up! A pleasure !!! @urotoday @OncoAlert
AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer. An AI model reading routine H&E slides pre-screened FGFR3 mutations with >93% sensitivity in advanced cases and could cut molecular testing by ~40%. #BladderCancer #AuthorCommentary with @Markuseckstein3 @UniFAU > bit.ly/4zB9Ht6 @NatureComms
8
16
1,175
Markus Eckstein retweeted
🧬🔬 MOSAIC is out in Genome Medicine! The Multi-Omics Spatial Atlas in Cancer: >2,700 tumor samples across ≥10 tumor types, generated in standardized labs at 5 founding partners (CHUV, Charité, UK Erlangen, Gustave Roussy, Pitt) together with Owkin (@OwkinScience) 📦 6 modalities from ONE FFPE block:
• H&E whole slide images
• Visium CytAssist spatial transcriptomics
• snRNA-seq (Chromium Flex)
• Bulk RNA-seq
• Whole exome sequencing
• Curated clinical data 🔓 MOSAIC Window, the first open release: 60 patients with bladder cancer, ovarian cancer, GBM, DLBCL and mesothelioma, available via EGA. Key findings:
🧩 Most tumors harbor ≥2 genomically, spatially and transcriptionally distinct malignant subsets (pan-cancer median 3, GBM median 6) 
🫧 Bladder cancer shows the highest inter-patient heterogeneity of all indications 
🔗 Tumor cell signaling tracks with its neighborhood: TGF-β ↔ fibroblasts, VEGF and JAK-STAT ↔ macrophages 
🧬 Copy number profiles do not always dictate transcriptomic state, pointing to passenger alterations 4 case studies with a therapeutic angle:
🎯 Mesothelioma: an inflamed, MET-active niche with high anti-PD-1 signature next to an immune-cold niche in the same tumor
🎯 Bladder: squamous/keratinizing vs. proliferative subsets independent of CN background; CEACAM5/6 confined to nest cores, relevant for ADC targeting
🎯 Ovarian: HRD signature restricted to one subset, suggesting heterogeneous PARPi sensitivity 💡 Bulk profiling averages out exactly the niches that may decide treatment response. Proud that Erlangen Pathology is a founding partner. Thanks to all patients, the Owkin team and every co-author 🙏. This is just the first step on a great journey with MOSAIC #PathTwitter #SpatialTranscriptomics #SingleCell #Multiomics #DigitalPathology #AIinPathology #PrecisionOncology #TumorHeterogeneity #BladderCancer #OpenData 📄 doi.org/10.1186/s13073-026-0…
5
13
806
Markus Eckstein retweeted
An introduction to MIBC (and mUC) in graphical narrative abstract. Please note: there are more subtype/variant histologies (there will be a separate thread in this).
🌶️🌡️Summary of my uropathology for urologists and oncologists series! 👉check it out! and retweet if you like! @urotoday @OncoAlert @Uroweb @EAUYAUrology @EAU_YAUroTech @EauPatient @niklas_kluemper @onkowissen nitter.gq/Markuseckstein3/status…
2
17
34
3,087
Markus Eckstein retweeted
🤖 Made with AI
11
26
1,285
Markus Eckstein retweeted
🔬 Great summary by @niklas_kluemper on KEYNOTE-905/EV-303 at #ESMO2026. Let me add the pathology angle, because his key question is ours to answer. The ad hoc analysis, 255 concurrently randomised, cisplatin-ineligible: 📊 2-yr EFS 41% / 56% / 76% (cystectomy / pembro / EV+P)
🔬 pCR 10% / 25% / 59%
📉 EFS HR 0.71 (0.47–1.07) for pembro, 0.40 (0.25–0.65) for EV+P
⚠️ Grade ≥3 TEAEs 42% / 70% / 69% Two things I keep coming back to 🧠 1️⃣ The toxicity numbers look reassuring and are not. 70 vs 69% grade ≥3 says EV adds no extra severe events, but a single rate collapses two very different profiles. Neuropathy, skin and metabolic toxicity in a curative-intent setting are not interchangeable with immune-related events, and they persist in survivors. Equal rates, unequal consequences. 2️⃣ 41% of patients on EV+P still have residual disease. We will not find them just with a IHC cutoff. Membranous Nectin-4, read on the membrane only, together with histological subtype and divergent squamous differentiation, is the most informative combination we already have and routinely leave unmeasured. And a pathology point that follows directly: once pCR carries this much weight, ypT0N0 at cystectomy becomes a high-stakes diagnosis. Thus, Sampling protocols and regression assessment need to be standardised and centrally reviewed, not left to local practice. 🎯 Also worth stating plainly: this is an ad hoc comparison, not a powered head-to-head. Pembro alone did not separate from surgery here (CI crosses 1). Interpret the three-arm ranking accordingly. Looking forward to Sunday's symposium. 🎤 ESMO 2026 | KEYNOTE-905/EV-303 | Abstract 4733O @niklas_kluemper @OncoAlert @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot #Uropathology #BladderCancer #blcsm #pathtwitter
15
26
1,486
Markus Eckstein retweeted
🚨 Perioperative immunotherapy in MIBC at #ESMO2026. Three phase III trials, three different answers, and one uncomfortable lesson for those of us who report pCR. 🔬 📊 NIAGARA (durvalumab + GC, n=1,063): pCR 37.3%, EFS HR 0.68 (0.56–0.82), OS HR 0.75 (0.59–0.95) ✅ 
📊 KEYNOTE-866 (pembrolizumab + GC, n=907): pCR 44.4%, EFS HR 0.88 (0.71–1.10), OS HR 1.00 (0.76–1.27) ❌ 
📊 CA017-078 (nivolumab + GC, n=653): pCR 39.1%, EFS HR 0.94 (0.71–1.25), OS HR 0.88 (0.64–1.21), OS immature ❌ Cross-trial, not head to head. Populations, schedules, follow-up (34 to 55 months) and statistical design all differ, so the ranking is exploratory. But look at the direction. The trial with the highest pCR returned an OS hazard ratio of exactly 1.00. 🧠 Three points from the pathology side: 1️⃣ pCR is a response marker, not a surrogate. Comparable absolute pCR gains of roughly 9 to 10 points across all three, divergent survival. If pCR tracked cure, that pattern should not be possible. pCR remains elusive at least for standard chemotherapy plus IO. 2. And pCR itself is not standardised across trials. ypT0N0 depends on sampling protocol, block numbers, regression assessment and whether review is central or local. The NIAGARA figure quoted here comes from a reanalysis, which tells you the endpoint moved on re-review. A 9-point difference is not comfortably above that measurement noise. Also worth noting: NIAGARA and KEYNOTE-866 both gave adjuvant IO, CA017-078 did not. So adjuvant continuation alone does not explain the split either. We genuinely do not know why these diverged. 🎯 Which is the real message. We are comparing trials on an endpoint we produce, that is not validated, not standardised, and not stratified by biology. Fixing that is a pathology job, and it is overdue. We need that now more than ever with neoadjuvant systemic phase becoming SOC. @OncoAlert @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot #Uropathology #BladderCancer #blcsm #MIBC #pathtwitter Great summary below from Niklas Klümper.
1
17
26
1,643
Markus Eckstein retweeted
What a great honor @niklas_kluemper ! Well deserved and you did a great job. Your dedication about urooncology brought you there and will even bring you far further - carry on my friend it is a pleasure and just fun working with you and trying to shape the UC sphere for the best of our patients!
1
7
24
1,116
Markus Eckstein retweeted
Really encouraging data. And trop2 is ubiquitous except for NEC and sarcomatoid. Exciting data for challenge!
SAC-TMT + pembro shows 68% response rates in metastastic bladder cancer #ESMO2026 . Trofuse-55 explores this combination in bladder sparing approaches in a randomized phase 3. The triplet with EVP seems a justified research randomised question. Triplet data from yesterday showed 81% RRs. @OncoAlert
4
12
650
Markus Eckstein retweeted
🚀 Is GU oncology becoming one of the most exciting fields for molecular imaging & theranostics? PSMA in prostate cancer, CAIX in clear-cell RCC, and emerging NECTIN4-targeted approaches in urothelial cancer! Fantastic to see CAIX imaging on the cover of The Lancet Medical Imaging & Theranostics. CAIX is a particularly elegant target: VHL loss → HIF stabilization → CAIX upregulation in ccRCC. Using tumor biology wisely! 🧬 The opportunity goes beyond detecting disease: molecular imaging could enable patient selection, visualize target heterogeneity and potentially guide radioligand therapy. Of course, CAIX-directed theranostics still require prospective validation, particularly of therapeutic efficacy and safety. Exciting times for precision GU oncology! 👏 Read here: sciencedirect.com/science/ar… @ProfKHerrmann #KidneyCancer #Theranostics #GUOncology @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
2
23
2
68
3,685
Markus Eckstein retweeted
🚨 How much adjuvant EV do we really need in MIBC? Same 3 neoadjuvant EV cycles. Two positive phase III trials. One major difference: 🔹 KEYNOTE-905/EV-303: 6 additional EV cycles after cystectomy 🔹 VOLGA: No adjuvant EV Peripheral neuropathy: 37% vs 18%. An absolute difference of 19 percentage points—approximately 1 additional neuropathy event per 6 patients treated. -> NNH 6! But ⚠️ these are cross-trial rates, not a randomized comparison. We cannot attribute the difference solely to adjuvant EV. With curative intent, cumulative neurotoxicity matters. Could pCR + postoperative ctDNA help identify patients who can safely omit adjuvant EV? Maximize cures. Minimize unnecessary toxicity. 🔬 #ESMO26 #BladderCancer @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
1
14
20
1,112
Markus Eckstein retweeted
Biomarker analysis exploring within-patient gene-expression ratios and deterministic single-sample predictions. This is an alternative to the high vs low classic approach @brian_rini #ESMO26
Several groups have attempted to predict the IM151 RCC clusters with flawed methods. We developed IRIS-RCC (Individual RNA-seq Intrinsic Subtyping for RCC; available at irisrcc.vindhyadatascience.c…), to predict clusters using an individual-sample model. nature.com/articles/s41698-0…
9
22
1,927
Markus Eckstein retweeted
AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer. An AI model reading routine H&E slides pre-screened FGFR3 mutations with >93% sensitivity in advanced cases and could cut molecular testing by ~40%. #BladderCancer #AuthorCommentary with @Markuseckstein3 @UniFAU > bit.ly/4zB9Ht6 @NatureComms
1
3
1
11
1,979
Thanks for picking our study up! A pleasure !!! @urotoday @OncoAlert
AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer. An AI model reading routine H&E slides pre-screened FGFR3 mutations with >93% sensitivity in advanced cases and could cut molecular testing by ~40%. #BladderCancer #AuthorCommentary with @Markuseckstein3 @UniFAU > bit.ly/4zB9Ht6 @NatureComms
8
16
1,175
Markus Eckstein retweeted
Dear colleagues, We are already curating THE COMPLETE #ESMO26 NEWSLETTER 📰 our picks of the top trials presented in Madrid, together in one email. Register to receive it 👉 buff.ly/N5gYtAc Every newsletter is curated by oncologists, for colleagues working in cancer care. It’s our way of making science quick and accessible. We are OncoAlert🚨 For Colleagues, by Colleagues Best, The Network @cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
2
25
12
44
11,233
Markus Eckstein retweeted
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer. ⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy. 🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it. #BladderCancer #GUOnc @OncoAlert @BladderCancerUS
4
61
1
119
10,738